The first 2 years of the COVID-19 pandemic were mainly characterized by recurrent
mutations of SARS-CoV-2 Spike protein at residues K417, L452, E484, N501 and P681 …

The COVID-19 pandemic caused by SARS-CoV-2 is associated with a lower fatality rate
than its SARS and MERS counterparts. However, the rapid evolution of SARS-CoV-2 has …

Effective treatments and vaccines against COVID-19 used in clinical practice have made a
positive impact on controlling the spread of the pandemic, where they are available …

Over three years' pandemic of 2019 novel coronavirus disease (COVID-19), multiple
variants and novel subvariants have emerged successively, outcompeted earlier variants …

Monoclonal antibodies are a promising treatment for COVID-19. However, the emergence of
SARS-CoV-2 variants raised concerns about these therapies' efficacy and long-term …

Background High-risk patients, often immunocompromised and not responding to vaccine,
continue to experience severe coronavirus disease 2019 (COVID-19) and death …

Convalescent plasma has been extensively tested during the COVID-19 pandemic as a
transfusion product. Similarly, monoclonal antibodies have been largely administered either …

Since the SARS-CoV-2 outbreak, pharmaceutical companies and researchers worldwide
have worked hard to develop vaccines and drugs to end the SARS-CoV-2 pandemic. The …

Allogeneic hematopoietic stem-cell transplantation (allo-HSCT) recipients are especially
vulnerable to coronavirus disease 19 (COVID-19), because of their profound …

COVID-19 pandemic is a global public health emergency. Despite extensive research, there
are still few effective treatment options available today. Neutralizing-antibody-based …